A Novel Approach to the Treatment of Plasma Protein Deficiency: Ex Vivo-Manipulated Adipocytes for Sustained Secretion of Therapeutic Proteins

Chemical & Pharmaceutical Bulletin
Masayuki KurodaKoutaro Yokote

Abstract

Despite the critical need for lifelong treatment of inherited and genetic diseases, there are no developmental efforts for most such diseases due to their rarity. Recent progress in gene therapy, including the approvals of two products (Glybera and Strimvelis) that may provide patients with sustained effects, has shed light on the development of gene therapy products. Most gene therapy products are based on either adeno-associated virus-mediated in vivo gene transfer to target tissues or administration of ex vivo gene-transduced hematopoietic cells. In such circumstances, there is room for different approaches to provide clinicians with other therapeutic options through a variety of principles based on studies not only to gain an understanding of the pathological mechanisms of diseases, but also to understand the physiological functions of target tissues and cells. In this review, we summarize recent progress in gene therapy-mediated enzyme replacement and introduce a different approach using adipocytes to enable lifelong treatment for intractable plasma protein deficiencies.

References

Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·N W BartonR O Brady
Jan 1, 1986·Differentiation; Research in Biological Diversity·H SugiharaK Yun
Aug 14, 2001·The Anatomical Record·C W Patrick
Oct 30, 2001·The Proceedings of the Nutrition Society·P Trayhurn, J H Beattie
Jun 5, 2003·Nature Genetics·Hiroyuki NakaiMark A Kay
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Erin E Kershaw, Jeffrey S Flier
Oct 14, 2004·Haemophilia : the Official Journal of the World Federation of Hemophilia·M K L ChuahT Vandendriessche
Apr 1, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Jaap RipJan Albert Kuivenhoven
Feb 20, 2007·Current Gene Therapy·Stefan F C VaessenJan Albert Kuivenhoven
Mar 21, 2007·Nature Medicine·Federico MingozziKatherine A High
May 15, 2007·Circulation Research·Jeffrey M GimbleBruce A Bunnell
Feb 16, 2008·British Journal of Haematology·Samuel L Murphy, Katherine A High
Apr 29, 2008·The New England Journal of Medicine·Albert M MaguireJean Bennett
Apr 29, 2008·The New England Journal of Medicine·James W B BainbridgeRobin R Ali
May 6, 2008·Nature·Kirsty L SpaldingPeter Arner
Sep 20, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Erik S StroesJan Albert Kuivenhoven
Dec 5, 2008·Digestive Diseases and Sciences·Susan E WozniakEldo E Frezza
Jan 31, 2009·The New England Journal of Medicine·Alessandro AiutiMaria-Grazia Roncarolo
Jul 28, 2010·The New England Journal of Medicine·Salima Hacein-Bey-AbinaMarina Cavazzana-Calvo
Sep 18, 2010·The Journal of Gene Medicine·Inge PetrusThierry VandenDriessche
Nov 12, 2010·The New England Journal of Medicine·Kaan BoztugChristoph Klein
Aug 9, 2011·Journal of Cardiovascular Translational Research·Zhu ChenHeather H Zhou
Dec 14, 2011·The New England Journal of Medicine·Amit C NathwaniAndrew M Davidoff
Mar 23, 2012·The Journal of Clinical Endocrinology and Metabolism·André C CarpentierDaniel Gaudet
Oct 2, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Seppo Ylä-Herttuala

❮ Previous
Next ❯

Citations

Mar 18, 2020·Conservation Biology : the Journal of the Society for Conservation Biology·Nadiah P KristensenRyan A Chisholm
Mar 4, 2020·Breast Cancer Research and Treatment·Takahito MasudaMasayuki Ohtsuka
Apr 20, 2021·Journal of Atherosclerosis and Thrombosis·Masayuki KurodaMariko Harada-Shiba

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.